Key result
Ticagrelor use for preventing recurrent type 1 and type 2 myocardial infarctions presents both potential clinical benefits and risks.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
John A. Bittl (2018) studied this question. Ticagrelor use for preventing recurrent type 1 and type 2 myocardial infarctions presents both potential clinical benefits and risks.
Synapse has enriched 10 related papers. Consider them for comparative context: